Key result
Only 40% of practitioners perform annual CVD risk assessments despite most considering them required.
Why the study?
The extent of cardiovascular disease risk monitoring in clinical oncology practice among cancer survivors was unknown.
Cross-Sectional (n=32)
No
Absolute Event Rate: 40% vs 77%
p-value: p=<0.001
There is a significant gap between the perceived need for annual cardiovascular risk monitoring in cancer survivors and actual clinical practice.
CVD monitoring in cancer survivors may lag in practice; leaves open standardized protocols and prospective studies.
There exist published literature for cardiovascular disease (CVD) risk monitoring in cancer survivors but the extent of monitoring in clinical oncology practice is unknown. We performed an interactive survey at a Royal College of Physicians conference (11 November 2016) attended by practitioners with an interest in late effects of cancer treatment and supplemented the survey with an audit among 32 lung cancer survivors treated at St Peter's NHS Hospital in 2012-2016. Among the practitioners, 40% reported CVD risk monitoring performed at least annually, which is compatible with European Group for Blood and Marrow Transplantation Guidelines, but 31% indicated that monitoring was never performed. In contrast, 77% felt that at least an annual assessment was required (p<0.001). Corroborating these data, among the lung cancer survivors, 31% and 16% had lipids or glucose/HbA1C measured annually, and 28% and 31% had never had these tests performed since their cancer treatment. Alerting healthcare providers to review protocols may help reduce CVD after cancer treatments.
No takes yet. Share an insight, caveat, or question.
Kapoor et al. (2017) conducted a cross-sectional in Cancer survivors (n=32). Cardiovascular disease risk monitoring was evaluated on Annual CVD risk monitoring performed vs required (p=<0.001). Although 77% of practitioners felt annual CVD risk assessment was required, only 40% reported performing it, and 28-31% of lung cancer survivors had never had lipids or glucose tested (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: